The Xenon NaV1.6 Inhibitor, NBI-921352 , is remarkably selective for the NaV1.6 sodium channel over other isoforms (IC50 = 51 nM, 756x vs. NaV1.1, 134X vs. NaV1.2, 276X vs. NaV1.7, >583X vs. 1.3, 1.4, 1.5). The molecule is It is being developed to treat pediatric patients with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and [...]
< 1 minute read
Oct. 6, 2021
NBI-921352: A NaV1.6 Inhibitor
NBI-921352
highly selective NaV1.6 sodium channel inh. entering Ph. II for seizures (100 mg TID) arylsulfonamide class bioRxiv Xenon Pharmaceuticals, Burnaby, Canada